#Multiple Myeloma Treatment Market

[sandyron456]

https://360.com.ng/read-blog/32879

8th Nov 2022  Multiple Myeloma Treatment Market SWOT Analysis, Future Growth, Major Key Players, Opportunity and Forecast 2030

As per Multiple Myeloma Research Foundation, multiple myeloma generally occurs in bone marrow particularly located in the pelvic bones, spine, ribs, and the area of the hips and shoulders

[stevenwilliam12]

Multiple Myeloma: Advancements and Future Outlook in Treatment

Multiple Myeloma, the second most common form of blood cancer following non-Hodgkin lymphoma, is characterized by the proliferation of malignant plasma cells in the bone marrow. These abnormal cells outnumber healthy blood cells, severely compromising the body's ability to function and fight infections. Early diagnosis and appropriate treatment are critical to managing the disease. Multiple Myeloma presents in various forms, including symptomatic (active disease), asymptomatic (smoldering myeloma), solitary plasmacytoma, and rare plasma cell leukemia, each requiring tailored diagnostic and therapeutic strategies.

Rising Prevalence and Demographic Trends

The prevalence of Multiple Myeloma is rising, especially in the elderly population. The incidence rate is highest among older adults, with over half of the cases diagnosed in males. This demographic shift is influencing the Multiple Myeloma drug, with a greater focus on therapies suited to the aging population.

Current Treatment Options and Therapeutic Innovations

Historically, Multiple Myeloma treatment has centered around chemotherapy, corticosteroids, and stem cell transplantation. However, the treatment landscape has evolved with the introduction of new therapies such as Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) Inhibitors, Monoclonal Antibodies, and groundbreaking CAR-T cell therapies.

Recent advancements include:

BLENREP (2020), an anti-BCMA immunoconjugate.

NINLARO (2015), the first oral proteasome inhibitor.

EMPLICITI (2015), which enhances immune response.

TECVAYLI (2022), a bispecific antibody redirecting T-cells.

DARZALEX (2015) and TALVEY (2023), targeting CD38 and refractory cases, respectively.

These therapies have extended survival rates and improved the quality of life for patients, making them dependent on continuous treatment.

Advances in Relapsed/Refractory Treatment

The treatment landscape for relapsed or refractory Multiple Myeloma is rapidly evolving, with FDA approvals of CAR-T therapies like ABECMA and CARVYKTI. Companies like Pfizer, Johnson & Johnson, and GSK are competing in this market, with their innovative therapies shaping the future of treatment. Despite challenges like the high cost of CAR-T therapies, ongoing improvements may enhance their accessibility.

Dominant Players and Market Trends

Bristol Myers Squibb (BMS) and Janssen (a subsidiary of Johnson & Johnson) dominate the Multiple Myeloma treatment market with their robust portfolios. Janssen's DARZALEX and TECVAYLI, along with BMS's CAR-T therapy ABECMA, are setting the standard in treatment innovation.

Moreover, the expiration of patents on drugs like REVLIMID has led to generic competition, but companies like BMS are focusing on new therapies such as CELMoDs (Iberdomide and Mezigdomide) to maintain their market presence.

Future Outlook

The Multiple Myeloma treatment market, valued at USD 21,300 million in 2023, is poised for significant growth through 2034. Factors such as rising incidence rates, adoption of newer treatments, and a strong pipeline of emerging therapies will drive this growth. Investment in research and development will be critical in introducing more effective treatments, particularly for a growing elderly population.

Conclusion

Multiple Myeloma treatment is undergoing a transformative period, with new therapies improving patient outcomes and expanding options for relapsed or refractory cases. As the market continues to grow, ongoing innovation and investment will be key to addressing the needs of patients and advancing treatment paradigms.

[priteshwemarketresearch]

Carfilzomib Market Overview and Regional Outlook Study 2024 – 2034

Carfilzomib Market Defination:

TheCarfilzomib Market refers to the economic and clinical landscape surrounding the pharmaceutical drug carfilzomib. Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of cancer affecting plasma cells in bone marrow. It functions by selectively inhibiting the proteasome, a complex protein-degrading machinery essential for cell function and survival. This inhibition leads to the accumulation of proteins within cancer cells, triggering cell death through apoptosis.

Print This Guide for Future Reference:https://wemarketresearch.com/reports/request-free-sample-pdf/carfilzomib-market/1493

Exploring the Carfilzomib Market: Advancements in Multiple Myeloma Treatment

In the realm of oncology, particularly in the treatment landscape of multiple myeloma, carfilzomib has emerged as a cornerstone therapy, offering new hope and improved outcomes for patients. This blog delves into the dynamic carfilzomib market, examining its impact, current trends, challenges, and future prospects.

Understanding Carfilzomib

Carfilzomib is a proteasome inhibitor approved for the treatment of relapsed or refractory multiple myeloma. It works by selectively and irreversibly binding to the 20S proteasome, disrupting protein degradation in cancer cells and inducing apoptosis. Approved by the FDA in 2012, carfilzomib has since been integrated into treatment protocols, often in combination with other agents like lenalidomide and dexamethasone.

Market Dynamics

Current Landscape: The Carfilzomib Market is driven by its efficacy in treating relapsed or refractory multiple myeloma, particularly in patients who have received prior therapies. Its mechanism of action and clinical benefits have positioned it as a valuable option in the treatment algorithm for multiple myeloma.

Treatment Advancements: Clinical studies have demonstrated that carfilzomib-based regimens prolong progression-free survival and overall survival compared to traditional therapies. Its approval marked a significant advancement in the management of multiple myeloma, offering a targeted approach to combating the disease.

Competitive Environment: Within the proteasome inhibitor class, carfilzomib competes with bortezomib and ixazomib, each offering unique profiles in terms of efficacy, safety, and administration convenience. Ongoing research aims to optimize carfilzomib’s use through novel combinations and sequencing strategies to maximize patient benefit.

Clinical Applications

Approved Indications: Carfilzomib is primarily indicated for use in combination with other agents for the treatment of relapsed or refractory multiple myeloma. Clinical trials are also exploring its potential in newly diagnosed patients and maintenance therapy settings, broadening its scope of application.

Future Directions: Research efforts are focused on expanding carfilzomib’s indications and understanding its synergies with emerging therapies such as immunomodulators, monoclonal antibodies, and cellular therapies like CAR-T cells. These endeavors aim to further improve treatment outcomes and offer personalized therapeutic approaches.

Carfilzomib Market Challenges and Opportunities

Challenges: Economic considerations remain a significant challenge in the adoption of carfilzomib, given its high cost as a biologic therapy. Managing treatment-related adverse events, such as cardiovascular complications and hematologic toxicities, also requires vigilant monitoring and proactive management strategies.

Opportunities: Advances in biomarker identification and personalized medicine offer opportunities to tailor carfilzomib-based therapies to individual patient profiles. Moreover, ongoing research into combination therapies and novel formulations aims to enhance efficacy while minimizing adverse effects, thereby improving patient adherence and outcomes.

Patient Impact and Healthcare Considerations

Patient Experience: For patients diagnosed with relapsed or refractory multiple myeloma, carfilzomib represents a crucial treatment option that can potentially extend survival and improve quality of life. Education and support programs play a vital role in helping patients manage treatment-related challenges and adhere to therapy.

Healthcare System Implications: Integrating carfilzomib into clinical practice requires healthcare providers to navigate complex treatment algorithms and ensure appropriate patient monitoring. Collaboration among multidisciplinary teams, including oncologists, hematologists, and supportive care specialists, is essential for optimizing patient care and outcomes.

Regulatory and Market Access

Regulatory Landscape: Regulatory approvals and reimbursement policies influence the accessibility of cCarfilzomib Market in different regions. Streamlining regulatory processes and demonstrating cost-effectiveness through real-world evidence are crucial for enhancing market access and patient affordability.

Market Expansion: As clinical data continues to evolve and new indications are explored, the carfilzomib market is poised for growth. Market expansion strategies should prioritize evidence-based medicine and stakeholder collaboration to drive adoption and improve patient access.

Conclusion

In conclusion, the carfilzomib market represents a significant advancement in the treatment of multiple myeloma, reflecting the transformative impact of targeted therapies in oncology. Its approval and integration into treatment protocols underscore a shift towards personalized medicine and multidisciplinary care approaches that optimize patient outcomes.

While challenges such as economic considerations and treatment-related adverse events persist, ongoing research and collaborative efforts among stakeholders are paving the way for continued innovation and improvement inCarfilzomib-Based Therapies. By addressing these challenges proactively, healthcare providers and pharmaceutical companies can ensure that carfilzomib realizes its full potential in improving the lives of patients battling multiple myeloma.

Stay informed and engaged with the latest developments in the carfilzomib market to contribute to advancements in oncology and patient-centered care.

[poonamcmi]

Bortezomib Market Estimated to Witness High Growth Owing to Rising Adoption of Proteasome Inhibitors

The bortezomib market is primarily driven by high incidence and prevalence of multiple myeloma across the globe. Bortezomib, which is commonly sold under the brand name Velcade among others, is a proteasome inhibitor primarily used for the treatment of multiple myeloma and mantle cell lymphoma.

The global proteasome inhibitor drug market size is valued at approximately US$ 24.54 million in 2024 and is expected to register a CAGR of 4.7% over the forecast period of 2024-2031. The introduction of novel proteasome inhibitors and their increasing adoption in the treatment of cancer are the major factors anticipated to propel market growth. Key Takeaways

Key players operating in the bortezomib market are Hikma Pharmaceuticals, Pfizer, Meitheal Pharmaceuticals, Novartis International AG, Bristol Myers Squibb, NATCO Pharma, Teva Pharmaceuticals, Dr. Reddy's Laboratories, Gland Pharma, Shilpa Medicare, Qilu Pharmaceutical, Scion Pharmaceuticals, Farmhispania Group, Coresyn, Chem-Stone (Guangzhou), Hubei Honch Pharmaceutical, Vinkem Labs, Icrom, TAPI Teva, and Chengdu Aslee Biopharmaceuticals.

The introduction of generic versions of Bortezomib Market Demand has led to increased adoption and lowered treatment costs. Moreover, ongoing clinical trials evaluating the efficacy of bortezomib in other cancer indications are expected to expand the eligible patient pool. Technological advancements in proteasome inhibitor development focused on overcoming resistance, reducing toxicity, and novel delivery systems are further anticipated to support market growth. Market Drivers

The primary factors driving the growth of the global bortezomib market include rising prevalence of multiple myeloma globally, increasing adoption of proteasome inhibitors in treatment regimens, availability of generic versions, and ongoing clinical research evaluating the efficacy of bortezomib in other cancer indications. Additionally, improving healthcare infrastructure and expenditures in emerging economies will further support the market growth during the forecast period. Current challenges in Bortezomib Market

The Bortezomib Market Size And Trends  faces several challenges primarily due to the presence of alternative therapeutic options for treating multiple myeloma (MM). Some of the major challenges include increasing generic competition from drugs like ixazomib and daratumumab which are leading to lower sales of bortezomib drugs. Further, the patents of bortezomib drugs have expired in several regions making them available in generic forms at lower costs. This increasing availability of low-cost generics is a major challenge faced by innovator bortezomib drug companies. Additionally, the adverse side effects associated with bortezomib drugs like neuropathy and thrombocytopenia require close patient monitoring during treatment posing operational challenges. Stringent regulations for drug approval is another regulatory challenge for new market entrants. SWOT Analysis

Strength: Well-established drug with proven efficacy and safety profile in treating MM. It was the first proteasome inhibitor approved and remains a standard of care. Weakness: Patent expiry has led to availability of low-cost generics reducing sales of innovator brands. Further, it causes serious side effects like neuropathy requiring cautious use. Opportunity: Emerging economies with growing cancer burden and healthcare spending present an opportunity. Combination therapies with other anti-MM drugs can boost its use further. Threats: Increasing competition from newer oral proteasome inhibitors and monoclonal antibody based therapies poses pricing and market share threats. Stringent regulations for approval delays market entry of new players.

Geographical regions with high market concentration

In terms of value, North America accounts for the largest share of over 40% of the global bortezomib market led by the US. This is due to established healthcare infrastructure and higher adoption of innovative therapies. Europe is the second major regional market with a value share of over 30% supported by favourable reimbursement policies. The Asia Pacific region is projected to be the fastest growing market during the forecast period due to rising healthcare expenditure, growing cancer incidence and increasing demand for cancer treatments from middle-income countries like China and India. Fastest growing geographical region

The Asia Pacific region is poised to exhibit the highest growth rate during the forecast period in the global bortezomib market. This is attributed to rising disposable incomes, growing awareness about cancer treatments, expansion of healthcare facilities and increasing private sector investment in pharmaceutical research in emerging economies like China and India. Large patient pools undergoing cancer treatment in Asia present lucrative opportunities for bortezomib drug makers looking to tap high future growth potential in this region. Get More Insights On, Bortezomib Market For More Insights Discover the Report In language that Resonates with you French, German, Italian, Russian, Chinese, Korean About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[heathcareforallworld]

Velcade Market Size, Share, Industry Trends, and Forecast 2032

Introduction

Velcade, also known by its generic name bortezomib, is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Since its approval, Velcade has significantly impacted the oncology market, offering a promising therapeutic option for patients with these malignancies. The global Velcade market is characterized by its dynamic nature, driven by advancements in oncology research, increasing incidence of hematologic cancers, and a growing focus on personalized medicine.

Market Size and Growth Dynamics

Velcade Market Size was estimated at 1.76 (USD Billion) in 2023. The Velcade Market Industry is expected to grow from 1.83(USD Billion) in 2024 to 2.5 (USD Billion) by 2032. The Velcade Market CAGR (growth rate) is expected to be around 4.01% during the forecast period (2024 - 2032). This growth is fueled by the rising prevalence of multiple myeloma and other related cancers, which are increasingly being diagnosed due to advances in diagnostic technologies. Furthermore, the aging population, which is more susceptible to cancer, is also contributing to the expanding market.

North America holds the largest market share, attributed to the region's advanced healthcare infrastructure, high adoption rates of new therapies, and a strong focus on research and development. Europe follows closely, driven by similar factors. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, spurred by increasing healthcare expenditures, improving access to cancer treatments, and rising awareness about hematologic cancers.

Market Share Analysis

Velcade, originally developed by Millennium Pharmaceuticals and marketed by Takeda Oncology, has maintained a dominant position in the proteasome inhibitor segment. Its efficacy, safety profile, and first-mover advantage have contributed to its strong market share. However, with the expiration of key patents, the market has seen the entry of generic versions, which has led to increased competition and a shift in market dynamics.

The introduction of generics has made the treatment more accessible, particularly in developing regions, but it has also put pressure on the market share of branded Velcade. Despite this, the brand continues to hold a significant share due to its established presence and the trust it has garnered among healthcare professionals.

Industry Trends

Several key trends are shaping the Velcade market:

Rise of Combination Therapies: The use of Velcade in combination with other drugs, such as lenalidomide and dexamethasone, is becoming increasingly common. These combination therapies have shown improved efficacy and are becoming a standard of care in multiple myeloma treatment protocols.

Focus on Personalized Medicine: With the growing emphasis on personalized medicine, there is a trend towards tailoring treatments based on individual patient profiles, which includes genetic makeup and disease characteristics. This approach is expected to drive demand for Velcade as part of personalized treatment regimens.

Increased Research and Development: The oncology sector continues to see significant investment in research and development, leading to the discovery of new therapeutic targets and treatment options. While this fosters innovation, it also intensifies competition as new drugs enter the market.

Patent Expirations and Generic Competition: The expiration of Velcade’s patents has opened the market to generic competition, leading to reduced prices and increased accessibility. This trend is expected to continue, particularly in cost-sensitive markets.

Expanding Indications: Research is ongoing to explore the potential of Velcade in treating other cancers and conditions beyond multiple myeloma and mantle cell lymphoma. If successful, these efforts could lead to new indications, further driving market growth.

Forecast Through 2032

The Velcade Market CAGR (growth rate) is expected to be around 4.01% during the forecast period (2024 - 2032). Key drivers of this growth include the increasing global cancer burden, advancements in cancer therapy, and the expansion of healthcare infrastructure in emerging markets.

However, challenges such as the rising cost of cancer treatment, the availability of alternative therapies, and regulatory hurdles may pose risks to market expansion. Additionally, the shift towards biosimilars and generics is likely to impact the market dynamics, particularly in terms of pricing and market share distribution.

The forecast period is also expected to witness a greater emphasis on real-world evidence and outcome-based reimbursement models, which could influence the adoption of Velcade and its competitors.

Conclusion

The Velcade market is poised for significant growth in the coming years, driven by a combination of factors including rising cancer incidence, advancements in treatment protocols, and the expanding reach of healthcare services. While challenges such as generic competition and pricing pressures exist, the overall outlook remains positive, with opportunities for growth in emerging markets and through the development of new therapeutic indications. As the oncology landscape continues to evolve, Velcade is expected to remain a key player, contributing to improved outcomes for patients worldwide.

[dan6085]

Here are the top 25 drugs by revenue for 2024, along with details about their sales performance and therapeutic uses:

1. **Keytruda (Merck)**

- **Revenue**: $17 billion

- **Use**: Cancer immunotherapy, primarily for melanoma and lung cancer.

2. **Humira (AbbVie)**

- **Revenue**: $12.4 billion

- **Use**: Treats autoimmune diseases like rheumatoid arthritis and Crohn's disease.

3. **Eliquis (Bristol-Myers Squibb/Pfizer)**

- **Revenue**: $12 billion

- **Use**: Anticoagulant for preventing blood clots.

4. **Opdivo (Bristol-Myers Squibb)**

- **Revenue**: $11.3 billion

- **Use**: Cancer treatment, particularly for lung cancer and melanoma.

5. **Imbruvica (AbbVie/Janssen)**

- **Revenue**: $9.5 billion

- **Use**: Treats blood cancers like chronic lymphocytic leukemia (CLL).

6. **Ozempic (Novo Nordisk)**

- **Revenue**: $13.8 billion

- **Use**: Diabetes management and weight loss.

7. **Biktarvy (Gilead)**

- **Revenue**: $11.8 billion

- **Use**: HIV treatment.

8. **Dupixent (Sanofi/Regeneron)**

- **Revenue**: $11.5 billion

- **Use**: Treats severe allergic conditions and asthma.

9. **Stelara (Janssen)**

- **Revenue**: $10.9 billion

- **Use**: Treats psoriasis and Crohn's disease.

10. **Darzalex (Janssen)**

- **Revenue**: $9.7 billion

- **Use**: Treatment for multiple myeloma.

11. **Gardasil/Gardasil 9 (Merck)**

- **Revenue**: $8.9 billion

- **Use**: HPV vaccine to prevent cervical and other cancers.

12. **Farxiga (AstraZeneca)**

- **Revenue**: $22.8 billion (total since launch)

- **Use**: Diabetes and heart failure treatment.

13. **Entresto (Novartis)**

- **Revenue**: $22.1 billion (total since launch)

- **Use**: Heart failure treatment.

14. **Xarelto (Johnson & Johnson/Bayer)**

- **Revenue**: $24.2 billion (total since launch)

- **Use**: Anticoagulant for preventing blood clots.

15. **Januvia (Merck)**

- **Revenue**: $53.7 billion (total since launch)

- **Use**: Type 2 diabetes management.

16. **Fiasp/NovoLog (Novo Nordisk)**

- **Revenue**: $44.5 billion (total since launch)

- **Use**: Fast-acting insulin for diabetes.

17. **Enbrel (Amgen)**

- **Revenue**: $84.9 billion (total since launch)

- **Use**: Treats rheumatoid arthritis and psoriasis.

18. **Lantus (Sanofi)**

- **Revenue**: $45 billion (total since launch)

- **Use**: Long-acting insulin for diabetes.

19. **Trulicity (Eli Lilly)**

- **Revenue**: $12 billion (projected)

- **Use**: Type 2 diabetes management.

20. **Rituxan (Roche)**

- **Revenue**: $30 billion (total since launch)

- **Use**: Treats certain types of cancer and autoimmune diseases.

21. **Atripla (Gilead)**

- **Revenue**: $15 billion (total since launch)

- **Use**: HIV treatment.

22. **Cyramza (Eli Lilly)**

- **Revenue**: $3 billion (projected)

- **Use**: Cancer treatment.

23. **Symbicort (AstraZeneca)**

- **Revenue**: $5 billion (projected)

- **Use**: Asthma and COPD treatment.

24. **Xgeva (Amgen)**

- **Revenue**: $2 billion (projected)

- **Use**: Prevents bone fractures in cancer patients.

25. **Zytiga (Janssen)**

- **Revenue**: $2 billion (projected)

- **Use**: Prostate cancer treatment.

These drugs represent a significant portion of pharmaceutical revenues, reflecting their therapeutic importance and market demand.

Sources

[1] Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter https://www.ipharmacenter.com/post/top-pharmaceutical-companies-by-revenues-in-2024

[2] 1 https://www.protectourcare.org/wp-content/uploads/2024/05/GREEDWATCH_2024_Q1_Summary.pdf

[3] These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024 https://finance.yahoo.com/news/5-prescription-drugs-generate-jaw-130000827.html

[4] Best selling drugs of 2023 | Top 10 drugs by revenues | Best selling pharmaceuticals | iPharmaCenter https://www.ipharmacenter.com/post/best-selling-drugs-of-2023-top-10-drugs-by-revenues-best-selling-pharmaceuticals-ipharmacenter

[5] 30 Most Valuable Drug Companies in 2024 https://finance.yahoo.com/news/30-most-valuable-drug-companies-133034192.html

[credenceresearchdotblog]

Global amyloidosis therapeutic treatment market is expected to develop at a compound annual growth rate (CAGR) of 7.60%, from its estimated USD 2251.2 million in 2023 to USD 4352.35 million in 2032.Amyloidosis is a rare and complex group of diseases characterized by the abnormal accumulation of amyloid proteins in tissues and organs. These proteins can lead to severe organ damage and potentially life-threatening complications. The therapeutic treatment market for amyloidosis is evolving rapidly, driven by advancements in medical research, the development of new drugs, and increasing awareness of this challenging condition.

Browse the full report at https://www.credenceresearch.com/report/amyloidosis-therapeutic-treatment-market

Market Overview

The global amyloidosis therapeutic treatment market is experiencing significant growth, fueled by a combination of rising incidence rates, expanding research initiatives, and increasing healthcare expenditures. The market encompasses a range of therapeutic options, including pharmacological treatments, supportive therapies, and emerging novel therapies.

Pharmacological Treatments

Pharmacological treatment options for amyloidosis primarily target the underlying cause of the disease or aim to alleviate symptoms. The market is currently dominated by drugs that target the specific types of amyloidosis:

1. AL Amyloidosis: This form of amyloidosis results from abnormal immunoglobulin light chains and is often associated with multiple myeloma. The treatment approach involves managing the underlying plasma cell disorder. Therapies include proteasome inhibitors such as Bortezomib and Carfilzomib, immunomodulatory drugs like Lenalidomide, and monoclonal antibodies such as Daratumumab. These drugs have shown efficacy in reducing the production of amyloidogenic light chains and improving patient outcomes.

2. ATTR Amyloidosis: Caused by the accumulation of transthyretin protein, ATTR amyloidosis is further classified into hereditary (hATTR) and wild-type (wtATTR) forms. The therapeutic landscape includes: - Tafamidis: This drug stabilizes the transthyretin protein, preventing its misfolding and aggregation. Tafamidis has demonstrated significant benefits in slowing disease progression and improving quality of life for patients with ATTR amyloidosis. - Diflunisal: An older non-steroidal anti-inflammatory drug, Diflunisal has been repurposed for ATTR amyloidosis treatment due to its ability to stabilize transthyretin. - Gene Silencing Therapies: Emerging treatments such as Patisiran and Inotersen use RNA interference and antisense oligonucleotides to reduce the production of transthyretin. These therapies have shown promise in clinical trials and represent a significant advancement in the treatment of ATTR amyloidosis.

Supportive Therapies

Supportive therapies play a crucial role in managing the symptoms and complications of amyloidosis. These include symptomatic management of heart failure, renal impairment, and neuropathy. For instance, diuretics and antihypertensive agents are commonly used to manage cardiac amyloidosis, while dialysis may be required for patients with renal involvement. Pain management and physical therapy are also essential for addressing neuropathic symptoms.

Emerging Therapies and Research

The amyloidosis therapeutic treatment market is witnessing a surge in research and development activities aimed at discovering innovative treatments. Key areas of focus include:

1. Monoclonal Antibodies: Researchers are exploring the use of monoclonal antibodies targeting amyloid deposits directly or modulating the immune system to enhance amyloid clearance.

2. Small Molecules: New small molecules are being developed to disrupt amyloid fibril formation or promote the disaggregation of existing fibrils. These compounds have the potential to offer new treatment options for various forms of amyloidosis.

3. Gene Therapy: Advances in gene therapy hold promise for addressing the genetic basis of hereditary amyloidosis. By correcting or replacing faulty genes, these therapies could potentially prevent or cure the disease.

Challenges and Opportunities

Despite the progress in amyloidosis treatment, several challenges remain. The rarity of the disease can lead to difficulties in diagnosis and treatment, and the high cost of innovative therapies can be a barrier to access for many patients. Additionally, the complexity of amyloidosis requires a multidisciplinary approach to manage the diverse manifestations of the disease effectively.

However, the growing investment in research and development, coupled with advancements in personalized medicine, presents significant opportunities for improving patient outcomes. Continued innovation and collaboration among researchers, healthcare providers, and pharmaceutical companies are essential to overcoming these challenges and advancing the treatment landscape for amyloidosis.

Key Players

Prothena Corporation Plc.

Eidos Therapeutics

Pfizer Inc.

SOM Biotech

Corino Therapeutics

Johnson and Johnson Services, Inc.

AstraZeneca Plc.

Alnylam Pharmaceuticals, Inc.

GlaxoSmithKline, Plc.

Others

Segmentation

By Type of Amyloidosis

AL Amyloidosis (Primary Amyloidosis)

ATTR Amyloidosis (Hereditary and Wild-Type)

AA Amyloidosis (Secondary Amyloidosis)

By Treatment Modalities

Chemotherapy

Immunomodulatory Drugs (IMiDs)

Monoclonal Antibodies

TTR Stabilizers

RNA Interference (RNAi) Therapies

Liver Transplantation

Supportive Care

By Disease Severity

Newly Diagnosed Patients

Relapsed or Refractory Disease

Advanced Disease

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/amyloidosis-therapeutic-treatment-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[wellnessweb]

Globalization and Market Expansion in Multiple Myeloma

The Multiple Myeloma Market size was estimated at USD 24.01 Billion In 2023 & is estimated to reach USD 59.45 Billion by 2032 and increase at a compound annual growth rate of 10.6% between 2024 and 2032.The Multiple Myeloma market is characterized by a dynamic interplay of research, treatment advancements, and patient-centric care initiatives. As one of the most prevalent hematologic cancers, it continuously draws attention from pharmaceutical innovators and healthcare providers alike. Recent years have witnessed a surge in targeted therapies, immunotherapies, and personalized medicine approaches tailored to combatting its complexities. This evolving landscape not only fosters competition among biopharmaceutical companies but also emphasizes the importance of early detection and multidisciplinary treatment strategies. With ongoing clinical trials promising novel therapeutic avenues, the Multiple Myeloma market remains poised for further breakthroughs in extending patient survival and enhancing quality of life.

The Multiple Myeloma Market  research study for the term also includes a variety of business opportunities and growth potential. A business plan detailing market risks and constraints as well as the effects of various regulatory regimes is given to executives by the market research. This is carried out to assist companies in reaching their main goals and making better judgments.

Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/3490

Market Segmentation

By Type

Chemotherapy

Monoclonal Antibody

Protease Inhibitors

Others

By Disease Type

Smoldering Multiple Myeloma

Active Multiple Myeloma

By End User

Clinics

Hospitals

Others

Regional Outlook

The geographical categories that make up the Multiple Myeloma Market  each have their own revenue, market share, sales, and growth rates. Among the important geographical areas covered in the market analysis are Europe, Asia-Pacific, South America, North America, and the Middle East and Africa. Latin America is expected to have a small market share in value, while North America is forecast to maintain its global leadership position and have a significant market share in both volume and value.

COVID-19 Impact Analysis

In the first half of 2020, the COVID-19 virus started to spread over the world, infecting millions of people and forcing major nations to implement work stoppage and foot restrictions. Nearly every area of the economy has suffered, with the exception of medical goods and equipment for life support, including the Multiple Myeloma Market .

Competitive Landscape

The competitive analysis section of the global Multiple Myeloma Market  offers details and insights on the participants. Among the details provided are information on competition, a market overview by business status, and revenue projections by region. These businesses use a variety of strategies, such as product launches, partnerships, alliances, technology advancements, and contracts, to boost market income.

Conclusion

The market research is supported by first-hand experience, qualitative and quantitative analysis by industry analysts, and comments from key market players and actors in the value chain. The study investigates parent industry trends, micro and macroeconomic data, governing factors, and market attractiveness on a segment-by-segment basis. The study also illustrates how different market factors might have a qualitative impact on market segmentation based on geography and Multiple Myeloma Market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Flash Chromatography Market Size

Cystic Fibrosis Market Size

Cancer Biopsy Market Size

Glaucoma Therapeutics Market Size

Genomics Services Market Size

[viral-spices]

Selecting the Best Pure Turmeric Powder: A Comprehensive Guide

Turmeric is a golden-yellow spice used for enhancing flavour, colour and nutrition to your food. There are several health benefits of turmeric powder as it boosts your immunity, improves your brain function and kidney health, control cholesterol and anxiety. Some studies suggest that it is also used for cancer treatment (pancreatic cancer, prostate cancer and multiple myeloma). Ancient people have been using turmeric for ages as it has several medicinal uses.

Choosing the right quality of turmeric powder is very important these days as a lot of adulterated qualities are available in the market. Irrespective of your uses, it is important that you choose the right pure turmeric powder. Below are some useful guidelines that will help you to choose the right quality of pure turmeric powder.

It is very important to analyse the source of raw materials when it comes to pure turmeric powder procurement. Go for brands who source their raw materials from well-known farms and follow organic practices.

Certifications does play a major role in understanding the quality of turmeric powder. Look for organic certified brands as they ensure that the turmeric powder you are buying is free from chemicals and pesticides. Check the packaging of the band if they have USDA organic, EU Organic or India organic logo.

Identification of pure turmeric powder can be determined by checking the colour and aroma. Pure turmeric powder is golden yellow colour and has a unique earthy aroma whereas inferior quality turmeric powder looks dull and have a mouldy aroma.

Pure turmeric powder can be determined by testing the presence of chemicals present in it. Mix one tablespoon of turmeric powder in a glass of water and dissolve it. If the waters turns pale yellow and the powder settles at the bottom, it is the right quality but if the water turns dark yellow then it is an adulterated quality.

Pure turmeric powder can also be identified by the curcumin percentage which is an active compound present in it. Curcumin in the main compound present in turmeric which has numerous health benefits. Look for the curcumin content embedded on the labels as high content indicates higher quality.

Cross check the packaging of the turmeric powder if it is properly sealed to ensure its freshness and reliability.

Before purchasing your turmeric powder give some time to read the reviews from other customers as their experiences can provide you valuable insights about the effectiveness and quality of the product.

Although price is not the sole factor albeit excessively cheap turmeric powder may be indicative of low quality. You should invest in a product that offers value for money and meets your required quality standards.

If you follow the above tips then you can confidently choose the right and pure turmeric powder that would suffice your requirements.

Although there are several organic turmeric powder manufacturers in India, Veerral Agro Tech/Kisan Agro leads the industry and convers all your needs. Every batch of organic turmeric powder supplied by Veerral Agro Tech/Kisan Agro is carefully manufactured and passes a stringent quality check to ensure highest level of customer satisfaction.

We not just provide you the quality of top notch but also ensure that the prices you get is highly competitive in the market. Seeking for a reliable organic turmeric powder manufacturers in India, visit us at www.viralspices.com and get your needs covered.

[sandyron456]

8th Nov 2022  Multiple Myeloma Treatment Market SWOT Analysis, Future Growth, Major Key Players, Opportunity and Forecast 2030

As per Multiple Myeloma Research Foundation, multiple myeloma generally occurs in bone marrow particularly located in the pelvic bones, spine, ribs, and the area of the hips and shoulders

[priteshwemarketresearch]

Carfilzomib Market Statistics, Segment, Trends and Forecast to 2034

TheCarfilzomib Market: Trends, Opportunities, and Future Outlook

Introduction

In recent years, the pharmaceutical industry has seen significant advancements in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Among these advancements, Carfilzomib has emerged as a critical player. This proteasome inhibitor, marketed under the brand name Kyprolis, has made substantial impacts in the management of multiple myeloma. In this blog, we will explore the current state of theCarfilzomib market, its growth drivers, opportunities, and future outlook.

Free Sample pdf copy:

What is Carfilzomib?

Carfilzomib is a next-generation proteasome inhibitor used in the treatment of multiple myeloma, especially in patients who have relapsed or are refractory to other therapies. Unlike its predecessor, bortezomib, Carfilzomib is known for its more selective action on the proteasome, potentially leading to fewer side effects and enhanced efficacy. Approved by the FDA in 2012, it has since become an integral part of combination therapies for multiple myeloma.

Carfilzomib Market Landscape

Growth Drivers

Rising Incidence of Multiple Myeloma: The increasing number of multiple myeloma cases globally is a significant driver for the Carfilzomib market. As the global population ages, the prevalence of multiple myeloma is expected to rise, leading to a higher demand for effective treatments.

Advancements in Treatment Protocols: Carfilzomib is often used in combination with other drugs like lenalidomide and dexamethasone, enhancing its effectiveness. This combination therapy approach has shown promising results, making Carfilzomib a preferred choice in advanced treatment regimens.

Increasing Awareness and Diagnosis: Improved diagnostic techniques and greater awareness about multiple myeloma have led to earlier detection and treatment. This trend is likely to boost the demand for Carfilzomib as part of first-line and subsequent lines of treatment.

Ongoing Clinical Trials: Continuous research and clinical trials exploring new indications and combination therapies for Carfilzomib are expanding its potential market. Studies focusing on different stages of multiple myeloma and other cancers could open new avenues for Carfilzomib use.

Carfilzomib Market Challenges

High Cost of Treatment: Carfilzomib is a high-cost drug, and its price can be a barrier to access, particularly in developing countries. The high cost of treatment may limit its market potential and lead to a preference for alternative therapies.

Side Effects and Resistance: Although Carfilzomib is well-tolerated, some patients may experience side effects such as cardiovascular issues or renal complications. Additionally, resistance to the drug can develop, leading to the need for alternative therapies.

Competition from Other Therapies: The multiple myeloma treatment landscape is competitive, with several other proteasome inhibitors and novel therapies in development. This competition can impact Carfilzomib’s market share and pricing strategies.

Market Opportunities

Expanding Indications: Research into expanding the use of Carfilzomib to other types of cancer or earlier stages of multiple myeloma could provide significant market opportunities. Successful clinical trials in these areas could lead to new indications and broaden its market.

Developing Markets: As healthcare infrastructure improves in developing regions, there ispotential for growth in these Carfilzomib Market Strategic partnerships and pricing strategies could enhance Carfilzomib’s reach in these areas.

Combination Therapies: Exploring new combination therapies and optimizing treatment regimens can improve patient outcomes and increase the demand for Carfilzomib. Collaborations with other pharmaceutical companies and research institutions could drive innovation in this space.

Carfilzomib Market Future Outlook

The Carfilzomib market is poised for continued growth driven by advancements in treatment protocols and increasing prevalence of multiple myeloma. However, challenges such as high treatment costs and competition from alternative therapies will require strategic planning and innovation.

The future of Carfilzomib will likely involve ongoing research and development to expand its therapeutic indications and improve patient outcomes. As the market evolves, stakeholders will need to navigate these dynamics to maximize the potential of Carfilzomib in the treatment of multiple myeloma and beyond.

Conclusion

Carfilzomib Market has made asignificant impact in the management of multiple myeloma, and its market prospects remain strong. With ongoing advancements in treatment protocols, increasing awareness, and expanding indications, Carfilzomib is set to continue playing a crucial role in cancer therapy. However, addressing market challenges and seizing emerging opportunities will be essential for stakeholders to fully realize the potential of this innovative drug.

[lenalidomidecost]

Understanding the Generic Revlimid Cost: What Patients Need to Know

As pharmaceutical patents expire, generic versions of brand-name drugs become available, potentially offering more affordable options for patients. This is particularly relevant in the case of Revlimid, a medication commonly prescribed for various blood cancers, including multiple myeloma and myelodysplastic syndromes. Understanding the generic Revlimid cost is crucial for patients and healthcare providers alike, as it can significantly impact access to treatment and healthcare budgets.

What is Revlimid?

Revlimid, whose active ingredient is lenalidomide, is a medication primarily used to treat multiple myeloma, a cancer that forms in plasma cells. It works by slowing or stopping the growth of cancer cells. Additionally, Revlimid is prescribed for certain types of myelodysplastic syndromes, a group of disorders in which the bone marrow does not produce enough healthy blood cells.

The Cost of Brand-name Revlimid:

Before the availability of generic alternatives, brand-name Revlimid was considerably expensive, often placing a significant financial burden on patients and healthcare systems. The high cost of brand-name medications can be a barrier to access for many patients, particularly those without adequate insurance coverage or financial resources.

Introduction of Generic Revlimid:

With the expiration of Revlimid’s patent, generic versions of the drug have entered the market. Generic drugs contain the same active ingredients as their brand-name counterparts and are approved by regulatory authorities as safe and effective. Generic Revlimid offers a more affordable alternative to the brand-name medication, potentially reducing healthcare costs and improving access to treatment for patients.

Factors Affecting Generic Revlimid Cost:

Several factors influence the cost of generic Revlimid, including competition among manufacturers, production costs, and healthcare policies. As more manufacturers produce generic versions of the drug, competition typically drives prices down, making it more affordable for patients. Additionally, healthcare policies, such as insurance coverage and government subsidies, can further impact the out-of-pocket cost of generic Revlimid for patients.

Accessibility and Availability:

While the availability of generic Revlimid may vary depending on the region and healthcare system, efforts are often made to ensure widespread accessibility. Healthcare providers and pharmacies may work closely with patients to facilitate access to generic medications, including Revlimid, through various channels such as prescription assistance programs and formulary optimization.

Consultation with Healthcare Providers:

Patients considering switching to generic Revlimid should consult with their healthcare providers to ensure that it is a suitable option for their condition. Healthcare providers can provide valuable guidance regarding medication options, potential cost savings, and any concerns or considerations specific to the individual patient.

Conclusion:

The availability of generic Revlimid offers a promising opportunity to improve access to essential cancer treatment while potentially reducing healthcare costs for patients and healthcare systems. Understanding the factors influencing the generic Revlimid cost is essential for patients and healthcare providers to make informed decisions regarding treatment options. By working collaboratively, patients and healthcare providers can navigate the landscape of generic medications and ensure access to quality care for individuals affected by blood cancers.

[123567-9qaaq9]

Minimal Residual Disease Testing Market  Future Trends to Look Out | Bis Research

Minimal Residual Disease Testing is a sophisticated diagnostic technique used primarily in oncology to detect and quantify residual cancer cells that may remain in the body during or after treatment. 

The Global Minimal Residual Disease Testing Market  is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients. 

The Minimal Residual Disease Testing  market was valued at $1.67 billion in 2023 and is expected to reach $6.67 billion by 2033, growing at a CAGR of 14.81% between 2023 and 2033. 

MRD Testing Overview 

Minimal Residual DiseaseTesting refers to the detection and quantification of residual cancer cells that remain in a patient after treatment, which are below the detection threshold of conventional diagnostic methods. MRD testing is particularly significant in hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, where even a small number of remaining cancer cells can lead to relapse.

Have a look at our sample page here !

Market Segmentation 

By Technology

By Target Detection 

By End Users 

By Region 

China dominated the Asia-Pacific Minimal Residual Disease Testing Market in 2022 with a share of 36.08%. Although the market is expected to remain in a strong growth phase due to the massively growing number of cancer cases and the rising health-related awareness among people in Asia-Pacific, a significant barrier to the increasing adoption is an uneven economic balance among countries within the region.

Importance of Minimal Residual Disease Testing Market  

Assessing Treatment Response 

Predicting Relapse 

Tailoring Therapy 

Key Factors

The  Minimal Residual Disease Testing Market  has experienced significant growth in recent years, driven by several key factors like 

advancements in technology

rising cancer burden, 

clinical evidence supporting MRD monitoring

Key Players In the  Minimal Residual Disease Testing Market  includes 

QIAGEN N.V.

Thermo Fisher Scientific Inc.

Sysmex Corporation

Mission Bio

OPKO Health

Bio-Rad Laboratories, Inc

 ICON plc

Hoffmann-La Roche

and many others 

Techniques used in Minimal Residual Disease Testing 

 Flow Cytometry - This technique uses fluorescent antibodies to identify cancer-specific markers on the surface of cells.

 Polymerase Chain Reaction- PCR amplifies cancer-specific genetic sequences, allowing for the detection of one cancer cell among a million normal cells. 

 Next Generation Sequencing - NGS provides detailed genetic information by sequencing DNA or RNA at high depth, offering unparalleled sensitivity and the ability to identify clonal diversity and mutations. 

 Digital Droplet PCR- A more recent advancement, ddPCR partitions the sample into thousands of droplets and performs PCR on each droplet individually, providing high sensitivity and precise quantification.

Applications for  Minimal Residual Disease Testing Market  

Treatment Response Monitoring

Relapse Prediction

Treatment Decision-making

Prognostic Assessment 

Clinical Trials and drug development 

Minimal Residual Disease Testing  Market Dynamics 

Market Drivers 

Advent of MRD and its Awareness among Consumers

Increasing Incidence of Cancer Cases Demanding MRD   

Rise in administration of solid tumors 

Expanding Medicare Coverage for MRD   

Recent Developments in the  Minimal Residual Disease Testing Market 

•Quest Diagnostics acquired Haystack Oncology, expanding its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition aimed to enhance personalized cancer care by offering highly sensitive diagnostic capabilities. Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel, a pioneering cancer research testing solution that has been enhanced and fine-tuned to include a broader range of single nucleotide variant (SNV) and indel coverage.

Visit our precision medicine page here! 

Key Questions Answered 

Q What is MRD   ? 

 Minimal residual disease (MRD) testing is a supplementary approach to detect extremely low levels of blood cancer cells and solid tumors following the treatment of conditions such as acute and chronic leukemia, lymphoma, or multiple myeloma. MRD specifically pertains to the minute population of cancer cells that persist in the body despite achieving complete remission (CR) through chemotherapy or stem cell transplantation.

Q What kinds of New Strategies are adopted by the existing market players to strengthen their positions in the Industry ? 

The global MRD   market is currently witnessing several developments, primarily aimed at introducing new products and services. Major manufacturers of MRD   products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

Conclusion 

In conclusion, Minimal Residual testing is a powerful tool in modern oncology, offering the potential to significantly improve patient outcomes through more precise and personalized treatment strategies.

[bhushans]

Global Focus on Improved Outcomes: Global Blood Cancer Treatment Market

The blood cancer treatment market  is poised for remarkable growth over the next decade. Valued at USD 5,935.9 million in 2023, the market is projected to expand to an impressive USD 15,735.3 million by 2033. This growth reflects a robust compound annual growth rate (CAGR) of 10.2% during the forecast period.

This significant rise is driven by advancements in medical technology, increasing prevalence of blood cancer, and heightened awareness and adoption of innovative treatment options. The promising forecast underscores the industry’s commitment to enhancing patient outcomes and combating one of the most challenging forms of cancer.

Request Your Detailed Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-1425

Industry stakeholders are optimistic about the future, as ongoing research and development efforts continue to yield new and effective therapies. The substantial market growth is expected to further accelerate the development and accessibility of life-saving treatments for blood cancer patients worldwide.

Understanding Blood Cancers: A Complex Disease

Blood cancers are a group of malignancies that affect the blood, bone marrow, or lymphatic system. These cancers disrupt the normal production of blood cells, leading to a variety of health issues. The four main types of blood cancer are:

Leukemia

Hodgkin lymphoma (HL)

Non-Hodgkin lymphoma (NHL)

Multiple myeloma

Key Takeaways:

The global blood cancer treatment market is expected to reach US$15,735.3 million by 2033, reflecting a significant rise from US$5,935.9 million in 2023.

This growth is projected at a robust compound annual growth rate (CAGR) of 10.2% throughout the forecast period.

Increased research and development efforts for novel therapies, coupled with rising cancer awareness initiatives, are key drivers for market expansion.

Combating Blood Cancers: A Focus on Innovation and Accessibility

The global blood cancer treatment market is experiencing significant growth, driven by a multi-pronged approach. Increased investment in research and development by key players is leading to the creation of novel and targeted therapies for various blood cancers, including leukemia, lymphoma, and multiple myeloma.

Competitive Landscape:

Some of the key participants present in the global blood cancer treatment market are:

Novartis Pharmaceuticals

Merck & Co. Inc.

Bristol-Myers Squibb Company

AbbVie Inc.

Johnson & Johnson Pvt. Ltd.

Celgene Corporation

Amgen Inc.

Teva Pharmaceutical Industries Ltd.

Bayer AG

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, and Novartis AG, account for a considerable market size, several regional-level players are also there operating across key growth regions, particularly in North America.

Recent Developments

In June 2021, Bayer announced that the company had submitted the supplemental new drug application (sNDA) to the USA Food and Drug Administration (FDA). The company had also applied to marketing authorization application (MAA) to the European Medicines Agency (EMA) for the oncology treatment combination of copanlisib and rituximab in the United States of America.

In 2021, Novartis announced strong data from the analysis of the pivotal Phase II ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma, with one-time Kymriah infusion, which showed an analysis of the ELARA trial demonstrated a 66% complete response rate and 86% overall response rate.

In February 2021, Bristol Myers Squibb announced that the company received approval for cancer immunotherapy from the USA Food and Drug Administration (FDA) for certain lymphomas. Further, the FDA approved the therapy as a treatment for adults who have certain types of non-Hodgkin lymphoma.

Key Segments Covered in the Blood Cancer Treatment Market Report:

By Application:

for Biological/Immunotherapy Applications

for Chemotherapy

for Radiation Therapy

for Targeted Therapy

for Stem Cell Transplantation

By End User:

in Hospitals

in Clinics

in Cancer Rehabilitation Centers

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan (APEJ)

Japan

The Middle East & Africa (MEA)

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology